ORMP logo

ORAMED PHARMACEUTICALS INC

ORMPNASDAQ
🏆 #3687 by market capEarnings Nov 11US Equity
$4.24▲ $0.07 (+1.68%)
Latest quote
🔔
Track ORMP
Get earnings, price moves & breaking news on Telegram
Track
24h▲ 1.7%
7d▲ 2.7%
14d▲ 1.6%
30d▼ 9.7%
ytd▲ 48.8%
1y▲ 78.9%
🏦Market Cap
$176M
Small Cap
📈Revenue Growth (YoY)
0.0%
Slowing
📊Gross Margin
0.0%
Thin
💵FCF Margin
0.0%
Thin
⚖️P/S Ratio
0.0x
Cheap
Otter Score
—
Insufficient data

Trading Snapshot

Day Range
$4.17 – $4.28
52-Week Range
$2.09 – $5.47
Volume (shares)
6,113
Avg Volume (shares)
—
Shares Outstanding
41.6M
Next Earnings
2026-11-11

Fundamentals Snapshot

Annual Revenue
$2M
Last Q Revenue
—
P/E Ratio
1.0
P/S Ratio
0.0x
EPS (TTM)
$4.26
Dividend Yield
6.01%
Dilution (1yr)
+1.3%
ORMP logo

ORAMED PHARMACEUTICALS INC

ORMP
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$2M
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
0.7%
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$15M▲ +18.1% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$11M▲ +31.4% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
40.5M▲ +1.3% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$45M▼ −$9M YoY
StockOtter · stockotter.space

About ORAMED PHARMACEUTICALS INC

Oramed Pharmaceuticals Inc., founded in 2002 and based in New York, New York, specializes in the development of groundbreaking pharmaceutical treatments. Their primary focus is on creating orally ingested capsules or pills for the delivery of polypeptides, particularly aimed at managing diabetes. The company's leading product, ORMD-0801, is an oral insulin capsule that has successfully completed Phase II clinical trials for patients with diabetes. Oramed is also advancing ORMD-0901, an oral glucagon-like peptide-1 (GLP-1) capsule, which has concluded Phase I clinical trials for the treatment of type 2 diabetes. Additionally, an oral leptin capsule for weight loss is currently under development. The firm was originally incorporated as Integrated Security Technologies, Inc., before officially changing its name to Oramed Pharmaceuticals Inc. in April 2006.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)

Insufficient data for all five components.

💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
💧Dilution★★★★★
Overall Score
Insufficient data
—/100

Analyst Ratings

ⓘ
Consensus
Sell
6 analysts
Strong Buy0
Buy0
Hold3
Sell1
Strong Sell2
Ratings as of Jun 2025

Latest News & Updates

News unavailable.